Nathan Connell: Applications Open for Global Hematology Research Training at Mass General Brigham
Nathan Connell, Clinical Chief of Hematology at Brigham and Women’s Faulkner Hospital, shared a post on LinkedIn:
“Interested in building a research career at the intersection of global health equity and hematology?
Despite remarkable advances in the diagnosis and treatment of inherited bleeding disorders, profound disparities persist in access to diagnosis, comprehensive care, and effective therapies around the world. Addressing these gaps requires more than clinical expertise.
It requires rigorous research, strong international partnerships, and the next generation of investigators committed to improving health outcomes globally.
I’m excited to share that the NIH/NHLBI-funded Global Non-Communicable Disease Research Training Program (T32) at Mass General Brigham is now accepting applications for the 2027–2028 academic year.
For physicians and scientists interested in global hematology, particularly hemophilia, von Willebrand disease, other inherited bleeding disorders, and nonmalignant hematologic conditions, this is an opportunity to develop research skills in clinical epidemiology, health services research, implementation science, diagnostics, and global health equity.
Led by Dr. Jessica Haberer, the program offers up to two years of supported postdoctoral research training, dedicated mentorship, structured research education through Harvard Medical School-affiliated programs, and engagement with an interdisciplinary community of global health investigators.
I would particularly encourage early-career hematologists and physician-scientists who want to study how we can improve the recognition, diagnosis, and delivery of care for people living with bleeding disorders in resource-limited settings to consider applying.
Through my work in inherited bleeding disorders, I have seen how critical it is to build research capacity that connects scientific advances with the realities of care delivery across different health systems.
Applications are due December 18, 2026, for a July 2027 start.
Applicants must hold an MD or PhD by the start of training and meet NIH citizenship or permanent residency requirements.
Prior affiliation with Brigham and Women’s Hospital or Massachusetts General Hospital is not required.”
Other posts featuring Nathan Connel on Hemostasis Today.
-
Oct 27, 2026, 22:52Danny Hsu: THANZ Makes History With Its First Dedicated HHT Symposium at Blood 2026
-
Oct 27, 2026, 16:28Rose Agor: Celebrating Two New Publications in Haematology Research
-
Oct 27, 2026, 16:21Pregnancy and Thrombosis-What Clinicians Need to Know – World Thrombosis Day
-
Oct 27, 2026, 16:13Lesley Van Wyk: DIC vs TTP vs HUS – The Key Diagnostic Clues
-
Oct 27, 2026, 16:02Ahmad G. Alzahrani: AF and Vascular Risk Factors – Should We Add Antiplatelet Therapy?
-
Oct 27, 2026, 16:02Iron Deficiency and Thrombocytosis: How Iron Availability Shapes Hematopoietic Lineage Decisions
-
Oct 27, 2026, 15:46Christiane Berger-Schaffitzel: New PhD Project Explores Snake Venom and Haemostasis
-
Oct 27, 2026, 13:51Muhammed Hajmusa: ESMO 2026 Highlights the Challenge of Anticoagulation in ROS1-Positive Lung Cancer
-
Oct 27, 2026, 13:39Luca Galassi: Retrieved Venous Thrombi as a Tool for Predicting Post-Thrombotic Syndrome